ESLA
Estrella Immunopharma, Inc.
Going-concern doubt
— flagged May 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, management has determined that there is a substantial doubt about its ability to continue as a going concern.”View the 10-Q filed May 18, 2026
Company with tickers: ESLA, ESLAW
CIK
1844417
CUSIP
297584104
Shares Outstanding
43,034,228
Website
https://www.estrellabio.com
Investor Relations
https://www.estrellabio.com/investors
13F Activity (30d)
1 filings
1 filers
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$1,000,000
as of 2024-01-30
· not restated in filings since 2024-02-14
Program Utilization
60.0%
$600,000 used of $1,000,000
| Program Announced | Authorized | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2024-01-30 | $1,000,000 | $400,000 | 2026-03-31 | — | 10-Q , filed 2026-05-18 |